GEHC
GE HealthCare Technologies Inc.Evidence as of 2026-09-02Overview · GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and…
Management team
- Mr. Roland Rott · CEO of UltrasoundFind on LinkedIn
- Mr. Kevin M. O'Neill · Chief Executive Officer of Pharmaceutical DiagnosticsFind on LinkedIn
- Dr. Taha Kass-Hout M.D., M.S. · Chief Science & Technology OfficerFind on LinkedIn
- Mr. Jan Makela · Chief Executive Officer of ImagingFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.1 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
Evidence balance: Mixed (+0.1 of a possible +2; was +0.1 before debate) · confidence high. Revenue for the period rose to $ 5,131,000,000 in the quarter ended 31 March 2026 (fiscal Q1 2026, 2026-04-22) from $ 4,777,000,000 in the comparable prior period, an increase of $ 354,000,000 (≈ 7.4%). Despite higher top line, gross profit fell from $ 2,012,000,000 to $ 1,977,000,000 and gross margin declined from about 42.1% to about 38.6%, and operating income moved down from $ 629,000,000 to $ 515,000,000 with operating margin falling from about 13.2% to about 10.0%.
Earnings per share compressed as diluted EPS fell from $ 1.23 to $ 0.85 in the same comparison. Reported long-term debt increased by $ 1,183,000,000 to $ 10,134,000,000 as of 31 March 2026, cash was reported at $ 2,261,000,000, and the dataset implies net debt near $ 8.0 billion. Market context shows price at $ 70.42, trailing EPS $ 4.12 (trailing P/E ≈ 17.09), elevated short-term volatility (vol_30d_annualized ≈ 44.2%), and mixed momentum (three‑month +13.6%, six‑month -9.8%).
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue in the quarter ended 31 March 2026 (fiscal Q1 2026, 2026-01-01 to 2026-03-31) was $5,131,000,000 compared with $4,777,000,000 in the quarter ended 31 March 2025 (fiscal Q1 2026 comparative period), an increase of $354,000,000 (≈7.4%).
XBRL companyfacts · 0001932393-26-000031Gross profit compressed from $2,012,000,000 in the quarter ended 31 March 2025 (fiscal Q1 2026 comparative period) to $1,977,000,000 in the quarter ended 31 March 2026 (fiscal Q1 2026); gross margin fell from about 42.1% to about 38.6% using reported revenue in those same periods.
XBRL companyfacts · 0001932393-26-000031Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
In the 10-Q filed 2026-07-29, management stated that, starting February 2025, U.S. tariffs "have materially impacted our financial results" and that "should the tariffs continue at current levels, we expect to continue to see a material impact."
10-Q filed 2026-07-29In the 10-Q filed 2026-07-29, management reported that tariffs negatively impacted Operating income by $68 million and $156 million for the three and six months ended June 30, 2026, respectively, and by $43 million and $52 million for the three and six months ended June 30, 2025, respectively.
10-Q filed 2026-07-29Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Three-month momentum is +13.6% as of 2026-09-01.
Moneyta signal set · 2026-09-01weakened in debateSix-month momentum is -9.8% and the 6-month relative strength vs SPY is -22.1%, with rank_momentum_6m at the 19th percentile of the 547-stock universe.
Moneyta signal set · 2026-09-01weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Institutional 13F-reported holdings total $27.00B across 1,258 holders as of the reported quarter ended 2026-03-31; reported aggregate 13F value was down 16.8% quarter-over-quarter with 201 exited positions and a net holder count decline of 77.
13F holdings · 1258 filers · as of 2026-03-31Top 13F holders in the reported quarter ended 2026-03-31 included BlackRock, Inc. ($2.56B), Dodge & Cox ($2.23B), VANGUARD CAPITAL MANAGEMENT LLC ($2.05B, noted as a new position), Capital Research Global Investors ($1.50B), and STATE STREET CORP ($1.46B).
13F holdings · 1258 filers · as of 2026-03-31Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A price-action piece on 31 August 2026 framed GE HealthCare’s movements as influencing institutional risk-allocation models.
News · news.stocktradersdaily.com · 2026-08-31Syndicated comparison headlines on 31 August 2026 asked whether GEHC or HAE is the better value option, appearing on Zacks and on Yahoo Finance.
News · zacks.com · 2026-08-31Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
CULP H LAWRENCE JR (Director) executed an open-market purchase of "$5.0M" for "80805" shares on 2026-05-06.
Form 4 · CULP H LAWRENCE JR (Director) · $5.0M bought · 2026-05-06Lobo Kevin (Director) executed an open-market purchase of "$642k" for "10000" shares on 2026-05-22.
Form 4 · Lobo Kevin (Director) · $642k bought · 2026-05-22Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The market price used in this evidence is $70.42 per share as of 2026-09-01.
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve‑month earnings per share (EPS) is $4.12, producing a trailing P/E of 17.09 in the provided dataset.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several claims jointly support a favorable read: reported revenue grew ~7.4% year-over-year in Q1 2026 while management obtained meaningful tariff refunds ($107M received, $38M receivable) that management recorded as pre-tax benefits; the company executed share repurchases ($100M in Q1) reducing share count modestly and multiple insiders made open-market purchases in May–August 2026. Management also recast segments (combining Imaging and Advanced Visualization into AIS), which can improve clarity of underlying business performance in reported results, and recent three‑month momentum is positive (+13.6%) with multiple sell‑side buy/initiations showing institutional analytical support. Taken together, these items strengthen the constructive interpretation of recent results versus focusing only on short‑term margin compression and headline leverage metrics.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.30
40 surviving claims rest on 20 distinct sources; the heaviest analyst carries 15% of them, and 96% of what the desk raised survived the debate.
The evidence base is moderately robust: 40 surviving claims drawn from 20 distinct sources means there is source diversity, and no single analyst dominates the set (the largest analyst contribution is 15%). However, a 96% survival rate through internal debate suggests little of the desk’s scrutiny overturned initial reads—useful for confidence, but also a flag that confirmatory persistence may be present. In short, the read can carry weight because it leans on primary filings and multiple data types, but remain mindful that a high survival rate can reflect consolidated views rather than aggressive falsification.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
14 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer−0.3 to the score
7 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.3 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
16 filings· 2 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot+1.0 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on GEHC Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.